LatchBio launches Antibody Discovery Benchmark: 100 evals testing AI agents' scientific decisions
kenbwork · x · 2026-09-03
LatchBio introduced the Antibody Discovery Benchmark, designed to test whether AI agents can make sound scientific decisions across the stages of therapeutic antibody discovery.
- 100 evaluations spanning ten areas, all drawn from concrete drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidate de-risking.
- The authors stress that antibody discovery is a multiparameter, context-dependent process: affinity must be weighed against specificity, stability, solubility, expression, and biological activity, and every measurement must be interpreted in the context of the experimental system that produced it.
- It's one of the first systematic benchmarks aimed at embedding AI agents into real wet-lab drug discovery decision chains.
More from Research
- Genomics researcher calls out popular benchmarks as opaque and flawed — anshulkundaje · 2026-09-03
- Counterfactual Debugging pinpoints sim2real failures via causal attribution at 1M steps — MichaelD1729 · 2026-09-03
- Expert: many popular genomics benchmarks are deeply flawed — publish their limits — anshulkundaje · 2026-09-03
- Untrained networks already tell cats from dogs: architectures as evolutionary selection — joannejang · 2026-09-03
- Stanford Prof. Anshul Kundaje: most public benchmarks in his field are badly biased — anshulkundaje · 2026-09-03
- CS professor builds AI system to preserve endangered languages and create new ones — begusgasper · 2026-09-03